Therapy of dyslipidaemia in patient with muscular dystrophy: case report


Authors: Ľubica Cibičková;  David Karásek
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in: AtheroRev 2019; 4(1): 35-37
Category:

Overview

We present a case report of a patient with muscular dystrophy and mixed dyslipidemia. He had a history of myocardial infarction and was indicated for therapy of dyslipidemia in secondary prevention. Statins were contraindicated due to pronounced elevation of creatinkinase. He did not reach goal of LDL-cholesterol level even on combined therapy with ezetimibe and fenofibrate. That is why we have decided for therapy with PCSK9 inhibitor, which was very well tolerated and helped to reach demanded LDL-cholesterol decrease.

Keywords:

muscular dystrophy – PCSK9 inhibitors – mixed dyslipidemia


Sources
  1. Zlatohlávek L, Vrablík M, Češka R. Hypolipidemická terapie v rukou praktického lékaře. Med Praxi 2011; 8(7): 316–320.
  2. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281–344. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.018>.
  3. Janský P, Rosolová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of Dyslipidaemias. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa 2017; 59(4): 389–415.
  4. Ambler Z, Bednařík J. Myopatie – základní charakteristika, klasifikace a perspektivy. Neurol Praxi 2004; 5(3): 135–136.
  5. Bednařík J. Svalové dystrofie. Neurol Praxi 2004; 5(3): 137–141.
  6. Schneider I, Stoltenburg G, Deschauer M et al. Limb girdle muscular dystrophy type 2L presenting as necrotizing myopathy. Acta Myol 2014; 33(1): 19–21.
  7. Sarwar N, Sandhu MS, Ricketts SL et al. [Triglyceride Coronary Disease Genetics, Consortium and Emerging Risk Factors Collaboration]. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375(9726): 1634–1639. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60545–4>.
  8. Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–1499. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501031>.
  9. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1500858>.
  10. Srivastava NK, Yadav R, Mukherjee S et al. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: In vitro, high-resolution NMR spectroscopy based observation in early phase of the disease. Magn Reson Imaging 2017; 38: 163–173. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mri.2017.01.001>.
  11. Sveen ML, Thune JJ, Køber L et al. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol 2008;65(9):1196–201. Dostupné z DOI: <http://dx.doi.org/10.1001/archneur.65.9.1196>.
  12. Sellers SL, Milad N, White Z et al. Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B. J Lipid Res 2018; 59(2): 261–272. Dostupné z DOI: <http://dx.doi.org/10.1194/jlr.M079459>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account